Edwards Lifesciences Analyst Ratings
Citigroup Maintains Buy on Edwards Lifesciences, Raises Price Target to $106
Citigroup Adjusts Price Target on Edwards Lifesciences to $106 From $105
Edwards Lifesciences Analyst Ratings
Evercore ISI Adjusts Price Target on Edwards Lifesciences to $91 From $89, Maintains In-line Rating
Deutsche Numis Sticks to Their Buy Rating for Edwards Lifesciences (EW)
Wolfe Research Adjusts Price Target on Edwards Lifesciences to $70 From $75
Edwards Lifesciences Analyst Ratings
Buy Rating Affirmed for Edwards Lifesciences on Growth and Market Positioning Prospects
Citi Upgrades Edwards, Tandem; Cuts Nevro, Establishment Labs
Edwards Lifesciences Analyst Ratings
Citigroup Upgrades Edwards Lifesciences to Buy From Neutral, Adjusts Price Target to $105 From $98
Robust Growth and R&D Focus Solidify Buy Rating for Edwards Lifesciences
Edwards Lifesciences Analyst Ratings
Edwards Lifesciences: A Buy Rating With Strong Growth Prospects and Positive Market Dynamics
Deutsche Bank Upgrades Edwards Lifesciences to Buy From Hold, Raises Price Target to $103 From $86
Edwards Lifesciences Analyst Ratings
Barclays: The Edwards Lifesciences (EW.US) rating was maintained, and the target price was adjusted from $100.00 to $101.00.
Barclays Adjusts Edwards Lifesciences Price Target to $101 From $100
Analysts Offer Insights on Healthcare Companies: Gossamer Bio (GOSS), RxSight (RXST) and Edwards Lifesciences (EW)